04 - References

References
Drug treatment of other psychiatric conditions
CHAPTER 9
References
Winsper C, et al. The prevalence of personality disorders in the community: a global systematic review and meta-­analysis. Br J Psychiatry
2020; 216:­69–­78.
Leichsenring F, et al. Borderline personality disorder: a review. JAMA 2023; 329:­670–­679.
Pascual JC, et  al. Pharmacological management of borderline personality disorder and common comorbidities. CNS Drugs 2023;
37:­489–­497.
Riffer F, et al. Psychopharmacological treatment of patients with borderline personality disorder: comparing data from routine clinical care
with recommended guidelines. Int J Psychiatry Clin Pract 2019; 23:­178–­188.
Paton C, et al. The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK mental
health services. J Clin Psychiatry 2015; 76:­e512–­e518.
Storebø OJ, et al. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev 2020; 5:CD012955.
Setkowski K, et al. Which psychotherapy is most effective and acceptable in the treatment of adults with a (sub)clinical borderline personality
disorder? A systematic review and network meta-­analysis. Psychol Med 2023; 53:­3261–­3280.
National Institute for Clinical Excellence. Borderline personality disorder: recognition and management. Clinical Guideline [CG78]. 2009
(last checked April 2022, last accessed January 2024); https://www.nice.org.uk/guidance/CG78.
Del Casale A, et al. Current clinical psychopharmacology in borderline personality disorder. Curr Neuropharmacol 2021; 19:­1760–­1779.
Gartlehner G, et al. Pharmacological treatments for borderline personality disorder: a systematic review and meta-­analysis. CNS Drugs 2021;
35:­1053–­1067.
Stoffers-­Winterling JM, et al. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev
2022; 11:CD012956.
ClinicalTrials.gov. Seroquel extended release (XR) for the management of borderline personality disorder (BPD). NCT00880919. 2017;
https://clinicaltrials.gov/study/NCT00880919?tab=results.
Black DW, et al. Comparison of low and moderate dosages of extended-­release quetiapine in borderline personality disorder: a randomized,
double-­blind, placebo-­controlled trial. Am J Psychiatry 2014; 171:­1174–­1182.
Han J, et al. A systematic review of the role of clozapine for severe borderline personality disorder. Psychopharmacology (Berl) 2023;
240:­2015–­2031.
ClinicalTrials.gov. Caplyta in borderline personality disorder. NCT05356013. 2023; https://clinicaltrials.gov/study/NCT05356013?
cond=Borderline%20Personality%20Disorder&page=2&rank=11.
ClinicalTrials.gov. Treating suicidal behavior and self-­mutilation in people with borderline personality disorder. NCT00533117. 2024;
https://clinicaltrials.gov/ct2/show/results/NCT00533117.
Bellino S, et al. Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study.
J Psychopharmacol 2010; 24:­333–­339.
Markovitz PJ, et al. Venlafaxine in the treatment of borderline personality disorder. Psychopharmacol Bull 1995; 31:­773–­777.
Kutcher S, et al. The successful pharmacological treatment of adolescents and young adults with borderline personality disorder: a preliminary open trial of flupenthixol. J Psychiatry Neurosci 1995; 20:­113–­118.
Lieslehto J, et al. Association of pharmacological treatments and real-­world outcomes in borderline personality disorder. Acta Psychiatr
Scand 2023; 147:­603–­613.
Essential Pharma Ltd. Summary of product characteristics. Camcolit 400mg prolonged release lithium carbonate. 2023; https://www.medicines.
org.uk/emc/product/10829/smpc.
ClinicalTrials.gov. Preliminary trial of the effect of glucocorticoid receptor antagonist on borderline personality disorder (BPD).
NCT01212588. 2019; https://clinicaltrials.gov/ct2/show/NCT01212588.
Fineberg SK, et al. A pilot randomized controlled trial of ketamine in borderline personality disorder. Neuropsychopharmacology 2023;
48:­991–­999.
Danayan K, et al. Real world effectiveness of repeated ketamine infusions for treatment-­resistant depression with comorbid borderline personality disorder. Psychiatry Res 2023; 323:115133.
Nandan NK, et al. ‘Esketamine’ in borderline personality disorder: a look beyond suicidality. Cureus 2022; 14:e24632.
Karaszewska DM, et al. Marine omega-­3 fatty acid supplementation for borderline personality disorder: a meta-­analysis. J Clin Psychiatry
2021; 82:20r13613.
Wollmer MA, et al. Clinical effects of glabellar botulinum toxin injections on borderline personality disorder: a randomized controlled trial.
J Psychopharmacol 2022; 36:­159–­169.
Links PS, et al. Prospective follow-­up study of borderline personality disorder: prognosis, prediction of outcome, and axis II comorbidity.
Can J Psychiatry 1998; 43:­265–­270.
Gardner DL, et al. Alprazolam-­induced dyscontrol in borderline personality disorder. Am J Psychiatry 1985; 142:­98–­100.